Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MOZEG
2023-509261-20-00Phase 2Authorised
- Sponsor
- Fakultní nemocnice Hradec Králové
- Start
- Mar 2025
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2 trial of albumin (human) in ischemic stroke (2 arms), sponsored by Fakultní nemocnice Hradec Králové. Primary endpoints: Serum syndecan-1 concentration and Urinary glycosaminoglycan (GAG) concentration. Planned start Mar 2025; status: authorised.
02
Drugs
albumin (human)
03
Conditions
ischemic stroke
Beyond the preview
Go deeper on 2023-509261-20-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-509261-20-00.